An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

✍ Scribed by Mark C. Genovese; Arthur Kavanaugh; Michael E. Weinblatt; Charles Peterfy; Julie DiCarlo; Michael L. White; Maryann O'Brien; Elliott B. Grossbard; Daniel B. Magilavy

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 183 KB
• Volume: 63
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.30114